DBV Technologies - ADR

XNAS:DBVT 4:00:00 PM EDT

16.43

+1.42 (+9.50%)

4:17:21 PM EDT: $16.45 +0.03 (+0.15%)

Market Cap (Intraday)	449.27M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.88 Million
Adjusted EPS	-$0.32

See more estimates

10-Day MA	$13.95
50-Day MA	$10.36
200-Day MA	$7.89

See more pivots

DBV Technologies - ADR Stock, XNAS:DBVT

177-181, avenue Pierre Brossolette, 107 avenue de la Republique, Chatillon, Hauts-de-France 92320

France

Phone: +33.1.55.42.78.78

Number of Employees: 104

http://www.dbv-technologies.com

Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, StÃ?Â©phane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.